Clinical Trial Detail

NCT ID NCT03973333
Title Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Immunocore Ltd
Indications

stomach cancer

lung non-small cell carcinoma

esophageal cancer

head and neck squamous cell carcinoma

transitional cell carcinoma

Therapies

Atezolizumab + IMC-C103C

IMC-C103C

Age Groups: adult senior

No variant requirements are available.